To report a case of severe neurological immune-related adverse events (N-irAEs) following treatment with pucotenlimab and review the literature on these events.
Key Findings:
N-irAEs are rare but can be life-threatening, with a higher mortality rate compared to other immune-related adverse events.
The patient developed severe neurological symptoms despite high-dose corticosteroid and plasma exchange therapy, indicating the refractory nature of these events.
Timely identification and intervention are crucial for managing high-grade N-irAEs, as they can significantly alter patient outcomes.
Interpretation:
The case highlights the challenges in diagnosing and managing severe N-irAEs, emphasizing the need for awareness, prompt treatment, and a multidisciplinary approach.
Limitations:
Limited data on the management of high-grade N-irAEs.
The case study is based on a single patient experience, which may introduce bias.
Conclusion:
The study underscores the potential severity of N-irAEs and the importance of early recognition and intervention in patients receiving immune checkpoint inhibitors, advocating for a multidisciplinary management approach.
